Abstract Title:

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Abstract Source:

Clin Rheumatol. 2007 Feb;26(2):258-60. Epub 2006 Jul 6. PMID: 16683176

Abstract Author(s):

Maria G Tektonidou, John Serelis, Fotini N Skopouli

Article Affiliation:

Department of Internal Medicine, Euroclinic Hospital, 9 Athanasiadou str, 115 21, Athens, Greece. [email protected]


Antitumor necrosis alpha agents have been successfully used for the treatment of rheumatoid and seronegative arthritis, Crohn's disease, psoriasis, and severe cases of vasculitis. Several side effects have been observed in patients receiving these agents including hypersensitivity reactions, infections, drug-induced lupus, or demyelinating syndromes. The presence of peripheral neuropathy has been reported only in isolated cases. We describe two cases of peripheral neuropathy which occurred in patients with rheumatoid arthritis receiving infliximab treatment, one with multifocal motor neuropathy with conduction block and another with axonal sensory polyneuropathy, reversed upon discontinuation of infliximab and intravenous gammaglobulin treatment.

Study Type : Human: Case Report
Additional Links
Problem Substances : Infliximab : CK(45) : AC(8)
Adverse Pharmacological Actions : Neurotoxic : CK(2744) : AC(664)

Print Options

Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.